Loading...

Orgenesis

Nasdaq:ORGS
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORGS
Nasdaq
$71M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The last earnings update was 100 days ago. More info.


Add to Portfolio Compare Print
  • Orgenesis has significant price volatility in the past 3 months.
ORGS Share Price and Events
7 Day Returns
-1.9%
NasdaqCM:ORGS
1%
US Biotechs
0.2%
US Market
1 Year Returns
-48.7%
NasdaqCM:ORGS
-4.6%
US Biotechs
2.9%
US Market
ORGS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orgenesis (ORGS) -1.9% -3.3% -15.4% -48.7% -3.5% -26.7%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • ORGS underperformed the Biotechs industry which returned -4.6% over the past year.
  • ORGS underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
ORGS
Industry
5yr Volatility vs Market
Related Companies

ORGS Value

 Is Orgenesis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Orgenesis. This is due to cash flow or dividend data being unavailable. The share price is $4.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orgenesis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orgenesis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ORGS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-11-30) in USD $-1.43
NasdaqCM:ORGS Share Price ** NasdaqCM (2019-05-23) in USD $4.4
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orgenesis.

NasdaqCM:ORGS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ORGS Share Price ÷ EPS (both in USD)

= 4.4 ÷ -1.43

-3.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orgenesis is loss making, we can't compare its value to the US Biotechs industry average.
  • Orgenesis is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Orgenesis's expected growth come at a high price?
Raw Data
NasdaqCM:ORGS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orgenesis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orgenesis's assets?
Raw Data
NasdaqCM:ORGS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-11-30) in USD $1.90
NasdaqCM:ORGS Share Price * NasdaqCM (2019-05-23) in USD $4.4
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqCM:ORGS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ORGS Share Price ÷ Book Value per Share (both in USD)

= 4.4 ÷ 1.90

2.32x

* Primary Listing of Orgenesis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orgenesis is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Orgenesis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Orgenesis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ORGS Future Performance

 How is Orgenesis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orgenesis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orgenesis expected to grow at an attractive rate?
  • Unable to compare Orgenesis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Orgenesis's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Orgenesis's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ORGS Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ORGS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ORGS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqCM:ORGS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-11-30 19 -16 -19
2018-08-31 16 -13 -13
2018-05-31 13 -9 -12
2018-02-28 11 -6 -12
2017-11-30 10 -4 -12
2017-08-31 9 -4 -17
2017-05-31 8 -3 -16
2017-02-28 7 -2 -17
2016-11-30 6 -4 -11
2016-08-31 6 -4 -7
2016-05-31 5 -4 -6
2016-02-29 4 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Orgenesis is high growth as no earnings estimate data is available.
  • Unable to determine if Orgenesis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ORGS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Orgenesis Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ORGS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqCM:ORGS Past Financials Data
Date (Data in USD Millions) EPS *
2018-11-30 -1.43
2018-08-31 -1.08
2018-05-31 -1.08
2018-02-28 -1.18
2017-11-30 -1.28
2017-08-31 -1.97
2017-05-31 -1.85
2017-02-28 -2.01
2016-11-30 -1.30
2016-08-31 -0.91
2016-05-31 -0.92
2016-02-29 -0.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Orgenesis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Orgenesis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Orgenesis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Orgenesis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Orgenesis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orgenesis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ORGS Past Performance

  How has Orgenesis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orgenesis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orgenesis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Orgenesis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orgenesis's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Orgenesis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orgenesis Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ORGS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-11-30 18.66 -19.18 16.30 6.46
2018-08-31 16.23 -13.11 11.98 4.03
2018-05-31 12.56 -11.98 11.15 2.63
2018-02-28 10.87 -11.85 10.26 2.50
2017-11-30 10.09 -12.37 9.19 2.48
2017-08-31 8.61 -17.36 9.51 2.40
2017-05-31 7.90 -16.06 7.60 2.68
2017-02-28 6.73 -17.46 7.35 2.50
2016-11-30 6.40 -11.11 6.24 2.16
2016-08-31 5.72 -7.27 5.58 1.97
2016-05-31 4.81 -6.24 5.26 1.49
2016-02-29 4.49 -3.45 4.28 1.29
2015-11-30 2.97 -4.46 3.78 1.07
2015-08-31 1.76 -3.01 3.81 0.37
2015-05-31 0.82 -4.89 3.29 0.92
2015-02-28 -5.58 3.17 1.12
2014-11-30 -5.50 3.03 1.55
2014-08-31 -7.71 3.20 2.46
2014-05-31 -5.16 3.69 1.84
2014-02-28 -4.92 3.69 1.57
2013-11-30 -5.54 4.01 1.45
2013-08-31 -5.22 3.65 1.50
2013-05-31 -6.16 4.06 1.30
2013-02-28 -5.47 3.38 1.56
2012-11-30 -5.00 2.68 1.80
2012-08-31 -3.67 1.94 1.23
2012-05-31 -1.79 0.59 1.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orgenesis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Orgenesis has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orgenesis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Orgenesis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orgenesis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ORGS Health

 How is Orgenesis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orgenesis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orgenesis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orgenesis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orgenesis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orgenesis Company Filings, last reported 5 months ago.

NasdaqCM:ORGS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-11-30 52.80 3.73 16.06
2018-08-31 48.61 2.82 16.74
2018-05-31 31.92 2.84 4.50
2018-02-28 23.36 4.53 4.23
2017-11-30 17.73 7.69 3.52
2017-08-31 11.25 8.01 0.76
2017-05-31 9.90 7.66 0.66
2017-02-28 5.72 10.46 3.95
2016-11-30 12.50 9.84 0.89
2016-08-31 13.84 8.89 0.27
2016-05-31 15.53 7.82 0.47
2016-02-29 16.68 7.55 0.93
2015-11-30 -6.44 10.28 4.17
2015-08-31 -5.96 10.13 0.26
2015-05-31 -5.05 9.27 0.19
2015-02-28 -3.62 2.52 0.52
2014-11-30 -2.98 2.45 1.31
2014-08-31 -4.10 2.63 1.54
2014-05-31 -1.59 0.00 0.02
2014-02-28 -1.70 0.37 0.25
2013-11-30 -2.03 0.26 0.06
2013-08-31 -1.31 0.26 0.53
2013-05-31 -0.97 0.24 1.08
2013-02-28 -0.26 0.00 0.06
2012-11-30 -0.28 0.00 0.01
2012-08-31 0.16 0.00 0.31
2012-05-31 -0.06 0.00 0.13
  • Orgenesis's level of debt (7.1%) compared to net worth is satisfactory (less than 40%).
  • Orgenesis had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orgenesis has less than a year of cash runway based on current free cash flow.
  • Orgenesis has less than a year of cash runway if free cash flow continues to grow at historical rates of 58.1% each year.
X
Financial health checks
We assess Orgenesis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orgenesis has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ORGS Dividends

 What is Orgenesis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orgenesis dividends.
If you bought $2,000 of Orgenesis shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orgenesis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orgenesis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ORGS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ORGS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orgenesis has not reported any payouts.
  • Unable to verify if Orgenesis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orgenesis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orgenesis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Orgenesis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orgenesis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orgenesis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ORGS Management

 What is the CEO of Orgenesis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vered Caplan
COMPENSATION $1,975,590
AGE 49
TENURE AS CEO 5.4 years
CEO Bio

Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer of Kamedis Ltd. since 2008. She serves as the Chief Executive Officer of BIC Inc. and Pbd Ltd. She served as an Interim President and Interim Chief Executive Officer of Orgenesis Inc. since December 23, 2013 until August 14, 2014. From 2004 to 2007, She served as the Chief Executive Officer of GammaCan International, Inc. She served as an Acting Chief Executive Officer of Gammacan International Inc. and GammaCan Ltd. from July 2, 2005 to April 15, 2006 and as Vice President of Business Development since March 1, 2005. Ms. Caplan served as Chief Executive Officer of GammaCan Ltd. from March 01, 2005 to May 22, 2007. She served as Vice President of Corporate Development at Gammacan International Inc. from May 22, 2007 to November 30, 2007. She is one of the most active entrepreneurs in the Israeli life sciences arena. She has been involved in the founding and management of more than ten ventures and has profound business development capabilities. She was involved in the founding and management of more than ten ventures in which she served in the Chief Executive Officer or senior management position, including: Critisense Ltd.; Serapis Ltd.; Cygnus Biotechnology Inc.; Drugon Biotechnology Ltd.; Barnev Ltd.; SloFlo Ltd.; Contipi LTD.; Mind Guard Ltd.; MTRE Ltd. and Meduck, Ltd. From 1997 to 1998, Ms. Caplan served as a Manager of Aran, one of the largest development companies in Israel with responsibility for investments in start-up medical. From 1995 to 1997, she served as a Manager for Medispec, LTD. She serves as the Chairperson of Orgenesis Inc. She served as Director of PEAK PHARMACEUTICALS, INC. (Formally known as Cannabis Therapy Corp.) from March 10, 2014 to April 6, 2016. She serves as Director of Opticul Ltd., Inmotion Ltd., Nehora Photonics Ltd., Ocure Ltd., Eve Medical Ltd., and Biotech Investment Corp. She served as a Director of MabCure, Inc., from April 2012 to October 2012. Ms. Caplan holds M.Sc. degree in Bio-Medical Engineering and Business Management from Tel Aviv University specialized in signal processing; management for engineers and a BSc degree in Mechanical Engineering from the Technion-Israel Institute of Technology specialized in software and cad systems.

CEO Compensation
  • Vered's compensation has increased whilst company is loss making.
  • Vered's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Orgenesis management team in years:

4.8
Average Tenure
48.5
Average Age
  • The tenure for the Orgenesis management team is about average.
Management Team

Vered Caplan

TITLE
Chairman
COMPENSATION
$2M
AGE
49
TENURE
5.4 yrs

Sarah Ferber

TITLE
Founder & Chief Scientific Officer
COMPENSATION
$269K
AGE
64

Neil Reithinger

TITLE
CFO, Secretary & Treasurer
COMPENSATION
$406K
AGE
48
TENURE
4.8 yrs

Denis Bedoret

TITLE
Managing Director of MaSTherCell
COMPENSATION
$289K
AGE
37
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Orgenesis board of directors in years:

6
Average Tenure
53
Average Age
  • The tenure for the Orgenesis board of directors is about average.
Board of Directors

Vered Caplan

TITLE
Chairman
COMPENSATION
$2M
AGE
49
TENURE
4.8 yrs

Guy Yachin

TITLE
Director
COMPENSATION
$231K
AGE
50
TENURE
7.1 yrs

Yaron Adler

TITLE
Director
COMPENSATION
$90K
AGE
47
TENURE
7.1 yrs

Zan Fleming

TITLE
Scientific Advisor
COMPENSATION
$67K
TENURE
7.1 yrs

Camillo Ricordi

TITLE
Scientific Advisor
COMPENSATION
$9K
TENURE
6.5 yrs

Jay Skyler

TITLE
Scientific Advisor
COMPENSATION
$9K
AGE
71
TENURE
6.1 yrs

David Sidransky

TITLE
Director
COMPENSATION
$120K
AGE
58
TENURE
5.8 yrs

Itamar Raz

TITLE
AGE
70
TENURE
4.2 yrs

Ashish Nanda

TITLE
Director
COMPENSATION
$17K
AGE
53
TENURE
2.3 yrs

Lorenzo Piemonti

TITLE
Member Scientific Advisory Board
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
08. Jan 19 Sell Hugues Bultot Individual 03. Jan 19 03. Jan 19 -300 $5.00 $-1,500
X
Management checks
We assess Orgenesis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orgenesis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ORGS News

Simply Wall St News

Is Orgenesis Inc.'s (NASDAQ:ORGS) CEO Paid At A Competitive Rate?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Vered Caplan's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$81m, and pays its CEO total annual compensation worth US$2.0m.

Simply Wall St -

Before You Buy Orgenesis Inc. (NASDAQ:ORGS), Consider Its Volatility

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Is Orgenesis Inc's (NASDAQ:ORGS) CEO Salary Justified?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Vered Caplan's Compensation Compare With Similar Sized Companies. … It would therefore appear that Orgenesis Inc pays Vered Caplan more than the median CEO remuneration at companies of a similar size, in the same market

Simply Wall St -

Should You Have Orgenesis Inc's (NASDAQ:ORGS) In Your Portfolio?

Broadly speaking, there are two types of risk you should consider when investing in stocks such as ORGS. … The first type is company-specific risk, which can be diversified away by investing in other companies to reduce exposure to one particular stock. … The second risk is market-wide, which arises from investing in the stock market.

Simply Wall St -

Does Orgenesis Inc's (NASDAQ:ORGS) CEO Pay Compare Well With Peers?

Performance can be measured based on factors such as earnings and total shareholder return (TSR). … I believe earnings is a cleaner proxy, since many factors can impact share price, and therefore, TSR. … Usually I would look at market cap and earnings as a proxy for performance, however, ORGS's negative earnings lower the usefulness of my formula.

Simply Wall St -

Why You Need To Look At This Factor Before Buying Orgenesis Inc (NASDAQ:ORGS)

Orgenesis has a beta of 1.8, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … Therefore, this is a type of risk which is associated with higher beta.

Simply Wall St -

Who Really Owns Orgenesis Inc (NASDAQ:ORGS)?

View our latest analysis for Orgenesis NasdaqCM:ORGS Ownership_summary Mar 29th 18 Institutional Ownership In ORGS's case, institutional ownership stands at 11.00%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … However, we should dig deeper into ORGS's ownership structure and find out how other key ownership classes can affect its investment profile. … Next Steps: ORGS's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Want To Invest In Orgenesis Inc (NASDAQ:ORGS)? Here's How It Performed Lately

Measuring Orgenesis Inc's (NASDAQ:ORGS) track record of past performance is a valuable exercise for investors. … I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years Orgenesis's top-line has risen by 66.82% on average, signalling that the company is in a high-growth period with expenses shooting ahead of revenues, leading to annual losses.

Simply Wall St -

ORGS Company Info

Description

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development services, such as manufacturing and development services, and contract manufacturing services. The PT Business segment focuses on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology. It also has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; and Columbia University. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

Details
Name: Orgenesis Inc.
ORGS
Exchange: NasdaqCM
Founded: 2008
$70,907,465
16,115,333
Website: http://www.orgenesis.com
Address: Orgenesis Inc.
20271 Goldenrod Lane,
Germantown,
Maryland, 20876,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ORGS Common Shares Nasdaq Capital Market US USD 20. Oct 2009
Number of employees
Current staff
Staff numbers
231
Orgenesis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:17
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2018/02/28
Last earnings filing: 2019/02/13
Last earnings reported: 2018/11/30
Last annual earnings reported: 2018/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.